Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use
18 August 2020 07:00 BST Imfinzi granted FDA Priority Review for less-frequent, fixed-dose use Option would extend dosing to four weeks in non-small cell lungand bladder cancer reducing medical visits by half AstraZeneca's Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer (NSCLC) and bladder cancer. If approved, Imfinzi could be administered intravenously every